Compugen (NASDAQ:CGEN) Stock Passes Above 200 Day Moving Average – What’s Next?

Posted by Stanley Muller on Sep 10th, 2026

Compugen Ltd. (NASDAQ:CGEN – Get Free Report)’s stock price crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $2.38 and traded as high as $2.63. Compugen shares last traded at $2.56, with a volume of 192,801 shares trading hands.

Wall Street Analyst Weigh In

CGEN has been the topic of several analyst reports. Weiss Ratings raised shares of Compugen from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Wednesday, August 5th. Leerink Partners dropped their price target on shares of Compugen from $13.00 to $5.00 and set an “outperform” rating for the company in a research report on Thursday, May 21st. Wall Street Zen lowered shares of Compugen from a “buy” rating to a “hold” rating in a report on Saturday, May 23rd. Finally, HC Wainwright restated a “buy” rating on shares of Compugen in a research report on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, Compugen presently has an average rating of “Buy” and an average target price of $5.00.

View Our Latest Analysis on CGEN

Compugen Stock Performance

The stock has a market capitalization of $232.59 million, a P/E ratio of 6.47 and a beta of 2.78. The stock has a 50-day moving average price of $2.44 and a two-hundred day moving average price of $2.39.

Compugen (NASDAQ:CGEN – Get Free Report) last announced its earnings results on Monday, August 3rd. The biotechnology company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. Compugen had a return on equity of 42.57% and a net margin of 47.56%.The company had revenue of $2.60 million during the quarter, compared to the consensus estimate of $1.28 million. During the same quarter in the prior year, the company earned ($0.08) earnings per share. Equities analysts anticipate that Compugen Ltd. will post -0.27 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Compugen

Institutional investors and hedge funds have recently modified their holdings of the stock. Bank Hapoalim BM bought a new stake in shares of Compugen during the 4th quarter valued at about $37,000. Security National Bank of Sioux City Iowa IA bought a new position in Compugen in the fourth quarter worth about $38,000. Franklin Resources Inc. bought a new position in Compugen in the second quarter worth about $56,000. Calamos Advisors LLC purchased a new stake in Compugen in the first quarter worth about $63,000. Finally, Hillsdale Investment Management Inc. purchased a new stake in Compugen in the first quarter worth about $68,000. 12.22% of the stock is owned by hedge funds and other institutional investors.

Compugen Company Profile

(Get Free Report)

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.